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Introduction {#sec005}
============

Cardiac surgeries in childhood are complex procedures in which every detail is important. On the one hand, the result of an intervention will vary depending on the type of congenital heart defect (CHD), the patient's situation before cardiac surgery, and the characteristics of the surgical techniques. On the other hand, optimal management after the surgery in the Intensive Care Unit (ICU) is also essential. In the ICU, multi-parameter monitoring, together with physical examinations, provide fundamental information about the situation of the patient, but they are limited in that they only tell us what is happening at that moment. Thus, any pre-operative information that could help us predict the evolution of the patient after cardiac surgery would be extremely valuable. One example of this is the widespread use of pre-surgery scores for predicting mortality risk after heart surgery; these are useful tools that allow for risk stratification prior to the intervention \[[@pone.0236377.ref001]\]. During the pre-surgical evaluation, the physical exploration and the echocardiogram can also help to estimate the risk of each patient by looking for signs of volume overload or heart failure.

Another great addition to our toolbox would be analyzing specific biomarkers before cardiac surgery, thus yielding useful and exact information. One such biomarker is adrenomedullin, a vasodilator protein with multiple functions, including the regulation of pulmonary blood flow. It has been associated with poor prognosis in children and adults with septic shock, and also in patients with cardiac failure \[[@pone.0236377.ref002]--[@pone.0236377.ref005]\], because of its functions as a compensatory protein: it stimulates myocardial contractility and coronary blood flow, increasing cardiac output. Mid-regional pro-adrenomedullin (proADM) levels rise in step with those of adrenomedullin, but it is a more stable peptide and is also easier to measure in the laboratory, which entails a great clinical advantage \[[@pone.0236377.ref006]\]. The other biomarker that could be of interest here is atrial natriuretic peptide, detected in the laboratory as mid-regional pro-atrial natriuretic peptide (proANP) \[[@pone.0236377.ref007]\]. This peptide is related to the brain natriuretic peptide \[[@pone.0236377.ref008]\] and its prohormone form pro-brain natriuretic peptide (proBNP) \[[@pone.0236377.ref009]--[@pone.0236377.ref013]\], and both have been studied after cardiac surgery. ProANP has been described as a good marker for heart failure in adults \[[@pone.0236377.ref014],[@pone.0236377.ref015]\], suggesting that it could be a good tool for stratifying risk before heart surgery.

Our hypothesis was that proADM and proANP levels prior to pediatric cardiac surgery might be higher in vulnerable patients that would need more intensive support throughout the post-operative period. The use of these biomarkers for this has not been described until now in children.

The main goal was to assess the usefulness of proADM and proANP before pediatric cardiac surgery in predicting a greater need for respiratory and inotropic support during the post-operative period. A secondary objective was to determine the relationship of these biomarkers with other complications that might arise after surgery.

Materials and methods {#sec006}
=====================

This was a prospective observational study performed in the Pediatric ICU of a pediatric tertiary referral hospital. All patients admitted after pediatric cardiac surgery from 2012 to 2013 were included, independently of their need for cardiopulmonary bypass. We excluded patients whose parents did not sign the informed consent form, as well as newborns admitted to the neonatal intensive care unit after cardiac surgery, because this is a different unit. The study was conducted in accordance with the Declaration of Helsinki and approved by the local research ethics committee (CEIm Fundación Sant Joan de Déu, Barcelona) and the institutional review board. Parental written informed consent was mandatory for recruited patients.

Serum levels of proADM and proANP were determined by immunofluorescence using Time-Resolved Amplified Cryptate Emission (TRACE) and a KRYPTOR analyzer (B·R·A·H·M·S Diagnostica GmbH, Henningsdorf, Germany). Detection limit values were 0.23nmol/L for proADM and 2.1pmol/L for proANP. A venous blood sample of 1 mL allowed for the analysis of both biomarkers. Values for proADM of \<0.5 nmol/L and for proANP of \<70 pmol/L were considered normal in children. The sampling times were always prior to cardiac surgery (pre-operative blood samples). The clinicians were blinded to the biomarker results during the study period.

Baseline data were collected: age at surgery, gender, weight, and previous surgeries. CHDs were divided into three categories following a classification based on the pathophysiology, as was done in previous studies \[[@pone.0236377.ref016]\]: (1) increased volume overload, (2) pressure overload involving the left ventricle or the right ventricle, (3) complex cyanotic CHD. Data about the heart surgery included the complexity of surgery score (STAT mortality scoring model \[[@pone.0236377.ref001]\]), type of surgery, and length of time for extracorporeal circulation, aortic cross clamping, and deep hypothermic circulatory arrest. The Pediatric Risk Mortality Score (PRISM III \[[@pone.0236377.ref017]\]) was calculated at admission. Respiratory support was considered as the total intubation time after surgery, measured by the number of hours on mechanical ventilation (MV) \[[@pone.0236377.ref018]\]. Hemodynamic support after cardiac surgery was analyzed using the vasoactive-inotropic score (VIS score \[[@pone.0236377.ref019]\]). The following complications after cardiac surgery were recorded: arrhythmia, low cardiac output syndrome (determined by echocardiography, left ventricular ejection fraction \<40%), pulmonary hypertension with clinical repercussions, and the need for renal replacement therapies and/or mechanical circulatory support. A major complication was defined as any one of the following occurring within the first 30 days after surgery: mortality, renal failure, neurological deficit, arrhythmia requiring a pacemaker, mechanical circulatory support, paralyzed diaphragm, or an unplanned operation \[[@pone.0236377.ref020]\]. Poor outcome was defined as mortality, cardiac arrest, use of mechanical circulatory support, renal replacement therapy, or neurologic injury (stroke or seizure), as in previous studies \[[@pone.0236377.ref021]\]. Mortality was described as any death occurring during the stay in the ICU. Prolonged length of stay (LOS) was as a LOS in the 75th percentile.

As done by previous studies \[[@pone.0236377.ref022]\], in order to detect specific differences linked to age, patients were divided into 3 age groups: newborns (\<1 month), infants (1--12 months), and children (\>12 months--18 years).

The primary endpoints were a greater need for respiratory support, defined as the need for more than 72 hours of MV after cardiac surgery \[[@pone.0236377.ref023],[@pone.0236377.ref024]\], and an increased need for inotropic support, assumed as a VIS score ≥20 points \[[@pone.0236377.ref021]\] during the first 24 hours after cardiac surgery. The secondary endpoints were the presence of complications after cardiac surgery (including poor outcome), prolonged LOS, and mortality.

The statistical analyses were performed using SPSS25.0®. The categorical variables were expressed as frequency and percentage, and the continuous variables were expressed as median and interquartile range (IQR). Data were analyzed via non-parametric tests, using the chi-squared test or Fisher's test as needed to compare categorical variables, and using the Mann-Whitney U test or the Kruskal-Wallis test for continuous variables. Spearman's rank correlation coefficient (r) was used to assess the associations between proANP and proADM before cardiac surgery and the continuous variables related to the patients' clinical characteristics, as well as the biomarkers' relationship with post-operative support needs. All tests were two-tailed. A receiver operating characteristic (ROC) analysis was performed, analyzing biomarker cut-off points, area under the curve (AUC), sensitivity (Sn), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV). A multivariate logistic regression was used to assess the association between the predictors and the primary endpoints. We performed a logarithmic transformation of proANP (*Ln*-proANP) and proADM (*Ln*-proADM) values in the regression model because they have a non-parametric distribution. Variables incorporated into the multivariate model were those with a p-value of \<0.2 in the univariate analysis and those with an elevated biological importance. All these results were expressed as odds ratio (OR) and 95% confidence interval (CI). A p-value of \<0.05 was considered significant.

Results {#sec007}
=======

A total of 113 patients were analyzed. The flow chart of patients is shown in [S1 Fig](#pone.0236377.s001){ref-type="supplementary-material"}. Fifty-nine (50.9%) were males. The main clinical characteristics of the patients are included in [Table 1](#pone.0236377.t001){ref-type="table"}.

10.1371/journal.pone.0236377.t001

###### Main demographic, surgical, and clinical characteristics of the patients.

![](pone.0236377.t001){#pone.0236377.t001g}

  Variables                                                                        Total patients (n = 113)
  -------------------------------------------------------------------------------- --------------------------
  Male                                                                             58 (51.3%)
  Age (years)                                                                      2.1 (0.6--6.6)
  Newborns                                                                         3 (2.7%)
  Infants                                                                          39 (34.5%)
  Children                                                                         71 (62.8%)
  Weight (kg)                                                                      12 (6.1--20)
  Underlying disease                                                               25 (22.1%)
  Previous cardiac surgery                                                         34 (30.1%)
  CHD with increased volume overload                                               59 (52.2%)
  CHD with pressure overload involving the left ventricle or the right ventricle   34 (30.1%)
  Complex cyanotic CHD                                                             20 (17.7%)
  STAT mortality category 1                                                        36 (31.9%)
  STAT mortality category 2                                                        47 (41.6%)
  STAT mortality category 3                                                        25 (22.1%)
  STAT mortality category 4                                                        4 (3.5%)
  STAT mortality category 5                                                        1 (0.9%)
  Univentricular physiology (Glenn or Fontan procedure)                            10 (8.8%)
  Extracorporeal circulation required                                              111 (98.2%)
  Length of extracorporeal circulation (minutes)                                   75 (55--100)
  Length of aortic cross clamping (minutes)                                        45 (29--68.5)
  Deep hypothermic cardiac arrest required                                         5 (4.4%)
  Length of deep hypothermic cardiac arrest (minutes)                              25 (6.5--35)
  PRISM III (points)                                                               3 (2--5)
  Need for mechanical ventilation at admission                                     49 (43.4%)
  Intubation time after surgery (hours)                                            4 (3--24)

Continuous variables are expressed as median (interquartile range) and categorical variables are expressed as frequency (percentage).

Nine patients (7.8%) required prolonged respiratory support and three patients (2.7%) required increased inotropic support. Four patients (3.5%) presented major complications and two (1.8%) had poor outcomes. The median LOS was 3 days (IQR 2--5). Only one patient died in the ICU (0.9%) during the study, 40 days after the surgery; this was a patient who needed ECMO after surgery due to myocardial ischemia, with a subsequent evolution towards dilated cardiomyopathy.

Biomarkers {#sec008}
----------

There were no differences as regards gender: proADM was 0.51 nmol/L (IQR 0.36--0.65) for males and 0.42 nmol/L (IQR 0.33--0.65) for females, with p = 0.213, proANP was 123.5 pmol/L (IQR 78.9--225.7) vs. 105.6 pmol/L (IQR 69.9--257.6), with p = 0.539. No differences were detected as regards univentricular physiology, either: proADM was 0.46 nmol/L (IQR 0.31--0.59) vs. 0.47 nmol/L (IQR 0.35--0.65), with p = 0.479, and proANP, 99.2 pmol/L (IQR 68.2--133.9) vs. 117.6 pmol/L (IQR 73.3--249), with p = 0.169. Patients in a higher STAT mortality category presented higher values of both biomarkers ([Fig 1](#pone.0236377.g001){ref-type="fig"}). A negative correlation was detected between age and the biomarkers: r = -0.678 for proADM and r = -0.716 for proANP (both p\<0.001). [Fig 2](#pone.0236377.g002){ref-type="fig"} illustrates the different values of the biomarkers depending on the age group, showing higher values in the youngest patients, especially newborns, with statistically significant differences between groups. There were also statistically significant correlations between the biomarker values and the intubation time after surgery (r = 0.427, p\<0.001 for proADM and r = 0.580, p\<0.001 for proANP). All the correlations between biomarkers and the main continuous characteristics of the sample are included in [Table 2](#pone.0236377.t002){ref-type="table"}.

![Differences between pro-atrial natriuretic peptide (proANP, pmol/L) and pro-adrenomedullin (proADM, nmol/L) according to the mortality risk category (STAT mortality category) before cardiac surgery.\
Values expressed as median (interquartile range) and compared using the Kruskal-Wallis test.](pone.0236377.g001){#pone.0236377.g001}

![Box plots showing the relationship between pro-atrial natriuretic peptide (proANP) and pro-adrenomedullin (proADM) and the three age groups.\
Boxes show the interquartile range and the median. The comparison using the Kruskal-Wallis test yielded p\<0.001 for the two biomarkers. Regarding the comparison between the two groups and proADM using the Mann Whitney U test: Newborns vs. Infants, p = 0.018; Newborns vs. Children, p = 0.005; Infants vs. Children, p\<0.001. For proANP: Newborns vs. Infants, p = 0.004; Newborns vs. Children, p = 0.004; and Infants vs. Children, p\<0.001.](pone.0236377.g002){#pone.0236377.g002}

10.1371/journal.pone.0236377.t002

###### Correlations between biomarkers and clinical data, using Spearman\'s rank correlation coefficient (*r*).

![](pone.0236377.t002){#pone.0236377.t002g}

  Clinical data                               ProADM *r*   *p*       ProANP *r*   *p*
  ------------------------------------------- ------------ --------- ------------ ---------
  **Age (years)**                             -0.678       \<0.001   -0.716       \<0.001
  **PRISM III (points)**                      0.318        0.001     0.300        0.001
  **Extracorporeal circulation (minutes)**    0.196        0.039     0.328        \<0.001
  **Aortic cross-clamping (minutes)**         0.253        0.011     0.382        \<0.001
  **VIS score after 24h (points)**            0.100        0.290     0.218        0.020
  **VIS score after 48h (points)**            0.289        0.002     0.321        0.001
  **Intubation time after surgery (hours)**   0.427        \<0.001   0.580        \<0.001
  **Length of stay (days)**                   0.312        0.001     0.362        \<0.001

VIS: Vasoactive-inotropic score. ProADM: pro-adrenomedullin. ProANP: pro-atrial natriuretic peptide.

Primary endpoints {#sec009}
-----------------

Patients with a greater need for respiratory and inotropic support after cardiac surgery presented higher values of both biomarkers in comparison with patients who did not. [Fig 3](#pone.0236377.g003){ref-type="fig"} illustrates these results.

![Box plots showing the relationship between the biomarkers (proANP and proADM) and a greater need for respiratory or inotropic support after cardiac surgery.\
Boxes show the interquartile range and the median. The comparison was done using the Mann-Whitney U test.](pone.0236377.g003){#pone.0236377.g003}

ProANP had a greater AUC than proADM for predicting increased respiratory support after cardiac surgery: AUC~proANP~ 0.791 vs. AUC~proADM~ 0.724, but there were no statistically significant differences between them (p = 0.494). [Fig 4](#pone.0236377.g004){ref-type="fig"} represents the AUC of both biomarkers. The combination of the two biomarkers had an AUC of 0.796 (95% CI 0.626--0.966, p = 0.003). A value of proANP ≥325 pmol/L had a Sn of 66.7% (95% CI 29.9--92.5), Sp of 88.8% (95% CI 81.2--94.1), PPV of 33.3% (95% CI 13.3--59.0), and NPV of 96.9% (95% CI 91.3--99.4) for predicting increased respiratory support needs.

![Receiver operating characteristic (ROC) analysis of proANP and proADM with respect to predicting increased respiratory support needs in children after cardiac surgery.](pone.0236377.g004){#pone.0236377.g004}

ProANP also had a greater AUC for predicting an increased need for inotropic support: AUC~proANP~ 0.948 (95% CI 0.874--1.000, p = 0.008) vs. AUC~proADM~ 0.855 (95% CI 0.688--1.000, p = 0.037), without statistically significant differences between them (p = 0.137). Their use in combination had an AUC of 0.912 (95% CI 0.780--1.000, p = 0.015).

In the multivariate analysis, the variable that remained as the independent predictor for increased need for respiratory support was Ln-proANP, with an OR = 3.575 (95% CI 1.684--7.591, p = 0.001), Hosmer--Lemeshow goodness of fit test = 0.321, and Nagelkerke's R^2^ = 0.260. The independent predictor for increased inotropic support needs was also Ln-proANP with an OR = 6.533 (95% CI 1.781--23.969, p = 0.005), Hosmer--Lemeshow goodness of fit test = 0.950, and Nagelkerke's R^2^ = 0.451.

Secondary endpoints {#sec010}
-------------------

Patients who presented any kind of complication had higher values of proANP: 249 pmol/L (IQR 80.2--482.7) vs. 107.7 pmol/L (IQR 70.1--200.7), p = 0.025. No differences were detected for proADM in the presence of any kind of complication (p = 0.295). Both biomarkers were higher in patients with poor outcome: proADM was 2.39 nmol/L (IQR 0.98--3.80) vs. 0.46 nmol/L (IQR 0.35--0.64) with p = 0.013, and proANP was 2052 pmol/L (IQR 1938--2166) vs. 112.0 pmol/L (IQR 73.5--226.4) with p = 0.001. [Table 3](#pone.0236377.t003){ref-type="table"} shows the biomarker values for the different types of complications.

10.1371/journal.pone.0236377.t003

###### Values of proADM and proANP in the presence of complications after surgery.
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  Variables                                        ProADM (nmol/L)     ProANP (pmol/L)       
  ------------------------------------------------ ------------------- --------------------- ----------------------
  Pulmonary hypertension                           Yes (n = 3)         0.46 (0.44--0.51)     80.2 (66.2-202-9)
  No (n = 110)                                     0.47 (0.35--0.65)   116.3 (73.7--229.3)   
  *p*                                              0.926               0.605                 
  Arrhythmia                                       Yes (n = 5)         0.63 (0.42--1.53)     343 (157.6--667.9)
  No (n = 108)                                     0.46 (0.35--0.64)   110.4 (73.4--222)     
  *p*                                              0.214               0.065                 
  Low cardiac output syndrome                      Yes (n = 5)         0.65 (0.46--0.66)     482.7 (155.4--782.3)
  No (n = 108)                                     0.46 (0.35--0.64)   110.4 (73.5--226.4)   
  *p*                                              0.494               0.102                 
  Neurological disability                          Yes (n = 2)         2.39 (0.98--3.80)     2052 (1938--2166)
  No (n = 111)                                     0.46 (0.35--0.64)   112 (73.5--226.4)     
  *p*                                              0.013               0.001                 
  Renal replacement therapy                        Yes (n = 2)         2.39 (0.98--3.80)     2052 (1938--2166)
  No (n = 111)                                     0.46 (0.35--0.64)   112 (73.5--226.4)     
  *p*                                              0.013               0.001                 
  Extracorporeal circulatory support               Yes (n = 1)         0.98                  1938
  No (n = 112)                                     0.46 (0.35--0.64)   113.7 (73.5--228.5)   
  *p*                                              0.230               0.053                 
  Major complication                               Yes (n = 4)         0.77 (0.34--3.09)     1140 (135.3--2109)
  No (n = 109)                                     0.46 (0.35--0.64)   112 (73.5--226.4)     
  *p*                                              0.320               0.074                 
  Prolonged length of stay                         Yes (n = 33)        0.62 (0.47--0.75)     191 (117.1--342.8)
  No (n = 80)                                      0.42 (0.33--0.57)   96.4 (66.7--177.0)    
  *p*                                              0.001               0.001                 
  Mortality in the pediatric intensive care unit   Yes (n = 1)         0.98                  1938
  No (n = 112)                                     0.46 (0.35--0.64)   113.7 (73.5--228.5)   
  *p*                                              0.230               0.053                 

Values are expressed as median (IQR) and compared using the Mann-Whitney U test.

Discussion {#sec011}
==========

As far as we know, this is the first study focused on the usefulness of measuring proANP and proADM before pediatric heart surgery. Our results suggest the ability of these biomarkers to predict an increased need for MV and inotropic support after cardiac surgery in children.

One of the advantages of using these biomarkers is that after drawing the blood sample, the result is available in only 30 minutes. Moreover, previous studies in adults have reported non-inferiority of proANP with respect to brain natriuretic peptide in many cardiovascular diseases \[[@pone.0236377.ref014],[@pone.0236377.ref025]\]. For these reasons, at our center we decided to analyze them during the pre-surgery visit.

These two biomarkers have been particularly well-studied in sepsis and cardiovascular diseases in adults. High levels are associated with a poor prognosis in septic patients \[[@pone.0236377.ref026]--[@pone.0236377.ref030]\]. The role of proADM in sepsis is linked to its biological function as both a potent vasodilator and compensatory protein. In children, proADM determined within the first 24 hours following cardiac surgery seems to predict a greater need for postoperative respiratory support \[[@pone.0236377.ref031]\]. According to our results, proADM values are also useful before cardiac surgery, because high values can predict an increased need for respiratory support.

Extubation is an important stage after cardiac surgery due to the interaction between the lungs and heart that can be affected by MV. Not all patients are good candidates for early extubation (\<6 hours after cardiac surgery). Today, anesthesiologists generally tend towards weaning in the operating theater if complications are not expected. The type of cardiac surgery and the patient's age are essential information when considering how soon to wean \[[@pone.0236377.ref023]\]. If a patient requires MV when they are admitted to the ICU, the weaning decision depends on the intensivist. We believe that proANP could be a good tool in this regard--a high value of proANP before cardiac surgery was related to an extended intubation time after surgery and could predict greater respiratory support needs after cardiac surgery, so this should alert the medical team not to proceed to weaning too soon. Many factors may influence the decision to extubate a child after cardiac surgery, so a single preoperative biomarker value would not serve as a stand-alone tool; rather, it could be another factor to consider before weaning.

ProANP rises in patients with heart failure due to its proprieties as a natriuretic, diuretic, and vasodilating agent. This protein is secreted in response to the increase in pressure inside the heart and in its dilating force. ProANP acts in the kidney, blood vessels, heart, adrenal glands, and adipocytes to carry out all its functions \[[@pone.0236377.ref032]\]. Its mechanism of action is linked to the compensatory strategy of the global system to regain balance after an injury. Its usefulness in adults for monitoring cardiac failure and myocardial infarction has been demonstrated \[[@pone.0236377.ref033],[@pone.0236377.ref034]\]. Some patients have heart failure before surgery despite the medical treatment, and these clinically unbalanced situations can lead to a worse post-operative evolution. This is consistent with our results, which showed that patients with higher pre-surgery proANP values required higher inotropic support after cardiac surgery. Furthermore, proADM also showed a good correlation with an increased need for inotropic support. This is consistent with the results of other studies, where proADM was higher in children with sepsis who required vasoactive drugs \[[@pone.0236377.ref035]\].

In addition, patients in a higher STAT mortality category presented higher levels of both biomarkers prior to surgery. To our knowledge, this has not been described before, so it might be useful information for the surgical team. Curiously enough, newborns also had higher values of the biomarkers. This may be due to the fact that this age range includes the most vulnerable patients and also has the greater number of complex surgeries. However, other biomarkers related to proANP, BNP and proBNP, also showed higher values in younger children, especially newborns \[[@pone.0236377.ref036],[@pone.0236377.ref037]\]. This fact suggests that newborns may present higher baseline values of proANP in comparison with older children. However, the increase of proANP after birth is higher than that of proBNP, but proANP levels drop fast and after day 4 of life, these proANP levels normalize \[[@pone.0236377.ref038]\], and in our sample, the surgeries were performed after that age. ProANP and proADM have been suggested as markers for the severity of neonatal sepsis \[[@pone.0236377.ref039]\] and proANP was also proposed as a marker for the evolution of patent ductus arteriosus \[[@pone.0236377.ref040]\]. Moreover, the age variable was excluded from the multivariate analysis performed.

BNP and proBNP have been the most commonly studied biomarkers for heart failure and major complications after heart surgery in children \[[@pone.0236377.ref009],[@pone.0236377.ref018],[@pone.0236377.ref020],[@pone.0236377.ref022],[@pone.0236377.ref036],[@pone.0236377.ref041]--[@pone.0236377.ref044]\]. However, their usefulness before cardiac surgery has not been standardized \[[@pone.0236377.ref013]\]. The release of proANP and proBNP and their functions run in parallel. BNP is also secreted by myocytes as a result of tension in the wall of the heart, and its levels seem to depend on the type of CHD rather than its severity \[[@pone.0236377.ref009]--[@pone.0236377.ref012],[@pone.0236377.ref022]\]. Both natriuretic peptides are good biomarkers of left ventricular impairment in adults with heart failure \[[@pone.0236377.ref045]\] and their correlation is optimal \[[@pone.0236377.ref015]\]. More has been published about BNP and proBNP in children due to its easier measurement and better reproducibility when compared to ANP \[[@pone.0236377.ref008]\]. However, the development of immunoassays \[[@pone.0236377.ref007]\] that analyze proANP has reduced the gap between the advantages of each, and our results regarding proANP are promising.

After seeing these results, one question comes to mind: which biomarker is better before cardiac surgery, proADM or proANP? Statistically speaking, both of them have demonstrated the ability to identify the most vulnerable patients before cardiac surgery. However, looking at the absolute numbers and the multivariate analysis, we believe that proANP is more useful and easier to interpret, because the differences of values between children with more or less need for inotropic and respiratory support are remarkably higher.

This is a preliminary study that analyzes, for the first time, the ability of these two biomarkers before pediatric heart surgery to predict the risk of complications after surgery. The most important limitations are the single-center design and the sample size. More studies are needed to increase our knowledge about these biomarkers, especially those focused on their usefulness before cardiac surgery and their relationship with the type of CHD and the possible individual variations. Younger patients should be analyzed separately, especially newborns, who are the most vulnerable patients, in order to explore cut-off points for each age group. The comparison of proANP and proBNP before cardiac surgery could also be of interest, since proBNP has been considered as the only biomarker for heart failure after cardiac surgery in children until now \[[@pone.0236377.ref036]\]. Analyzing proANP before cardiac surgery, combined with looking at a mortality risk score like the STAT mortality category, could change the stratification of these patients due to the ability of this biomarker to identify the most vulnerable patients.

In conclusion, a high proANP value before cardiac surgery should alert anesthesiologists and intensivists that the patient will probably need longer MV and more inotropic support during the post-operative period. Nevertheless, more studies are needed to confirm these results and explore further applications for these biomarkers.

Supporting information {#sec012}
======================

###### Flow chart of patients.

(TIFF)

###### 

Click here for additional data file.
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a\) Please amend your current ethics statement to include the full name of the ethics committee/institutional review board(s) that approved your specific study.

b\) Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE ethical requirements for human subjects research, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-human-subjects-research>.

3\. Thank you for stating the following financial disclosure:

\"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

At this time, please address the following queries:

Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.State what role the funders took in the study. If the funders had no role in your study, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."If any authors received a salary from any of your funders, please state which authors and which funders.If you did not receive any funding for this study, please state: "The authors received no specific funding for this work."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I read with interest the article entitled " Pro-atrial natriuretic peptide and pro-adrenomedullin before cardiac surgery in children. Can we predict the future?" The subject is interesting and quite innovative, sample size good. Results are interesting and consisting. The article however has a few limitations that should be addressed.

Major comments

-English and format need to be revised.

-Abstract and introduction are a bit wordy.

Methods:

\- A prospective study conducted almost ten years ago (2012-2013)?

\- Sample time is only pre-operative? When? The lack of post-surgical values is a clear limitation of the present work

-Complicated outcome and major complications after pediatric cardiac surgery definitions should be consistent with literature. We advise to see and cite similar articles on other biomarkers

Cantinotti M, Giordano R, Scalese M, Molinaro S, Della Pina F, Storti S, Arcieri L, Murzi B, Marotta M, Pak V, Poli V, Iervasi G, Kutty S, Clerico A.Prognostic role of BNP in children undergoing surgery for congenital heart disease: analysis of prediction models incorporating standard risk factors. Clin Chem Lab Med. 2015 Oct;53(11):1839-46.

Cantinotti M, Storti S, Lorenzoni V, Arcieri L, Moschetti R, Murzi B, Spadoni I, Passino C, Clerico A.

The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery.

Clin Chem Lab Med. 2012 Nov;50(11):2009-17

Cantinotti M, Lorenzoni V, Storti S, Moschetti R, Murzi B, Marotta M, Crocetti M, Molinaro S, Clerico A, Portman M, Iervasi G Thyroid and brain natriuretic Peptide response in children undergoing cardiac surgery for congenital heart disease- age-related variations and prognostic value. Circ J. 2013;77(1):188-97.

Methods and results:

-Did you evaluate differences among neonates, infants, and children? If not, it may be of worth since for BNP the trend was quite different. You state something in the limitation section, but this point should be elucidated and detailed better, also in the tables.

-In the tables please specify the type of CHDs

-Inclusion/exclusion criteria re not well defined. Did you include only cardiopulmonary bypass surgery?

Discussion: comparison with other biomarkers are required

Limitation section need to implement.

Minor comments

CVC= I would rather use pediatric cardiac surgery without abbreviation

Reviewer \#2: To the Authors

General Considerations

The aim of this study was to evaluate the utility of proANP and proADM determined before cardiovascular surgery for predicting need for high respiratory or inotropic support in the post-operative period. Authors enrolled 113 patients (51% males, median age 2.1 years, interquartile range 0.6-6.6 years) admitted to the neonatal intensive care unit after cardiovascular surgery. Authors considered as primary endpoints were a high respiratory support, considered as the need for more than 72 hours of mechanical ventilation after cardiovascular surgery, and a high inotropic support, in the first 24 hours after surgery. Furthermore, Secondary endpoints were the presence of complications after surgery, including Prolonged length of stay in ICU and mortality. The most important result of this study is that a high proANP determined before cardiovascular surgery may identify those patients who will need higher respiratory and inotropic support in the post-operative period.

The manuscript is concise and the results are clearly reported. I have only one observation to address to the Authors. It is well known that B-type natriuretic peptides (especially BNP and NT-proBNP) are the first line biomarkers for screening of heart failure and are also reliable prognostic markers in children undergoing cardiac surgery (Authors should cite the important review: Cantinotti M et al. Heart Fail Rev 2014;19:727-42). Therefore, the original data related to this article are that also some A-type natriuretic peptides, such as proANP, can have a prognostic role in paediatric patients admitted to the neonatal intensive care. Authors should explain because clinicians should prefer the assay of proANP in respect to that of BNP or NT-proBNP in children undergoing cardiac surgery. Accordingly, an important limitation of this study is that Authors should due to compare the prognostic accuracy of proANP to that of BNP or NT-proBNP. Authors should discuss this important point in revised manuscript.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Massimiliano Cantinotti

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1: I read with interest the article entitled " Pro-atrial natriuretic peptide and pro-adrenomedullin before cardiac surgery in children. Can we predict the future?"

The subject is interesting and quite innovative, sample size good. Results are interesting and consisting. The article however has a few limitations that should be addressed.

Dear Reviewer, Thank you very much for your valuable comments. Undoubtedly, all your suggestions have helped improve the quality of this manuscript. We hope we have adequately answered all queries. Please let us know if further changes are required.

Major comments

-English and format need to be revised.

-\>Dear reviewer, the manuscript was revised by a professional English translator. The changes related to the language editing were not marked. The format follows the journal guidelines.

-Abstract and introduction are a bit wordy.

-\>Dear reviewer, following your recommendations, changes have been made in the abstract and introduction.

Methods:

-A prospective study conducted almost ten years ago (2012-2013)? Sample time is only pre-operative? When? The lack of post-surgical values is a clear limitation of the present work.

-\> Dear reviewer, the project of the present prospective study included the analysis of proADM and proANP before surgery, immediately after surgery and between the 24--36 hours after surgery. However, a primary analysis was made only with the samples in the postoperative period (published in 2019, reference 31), and the pre-surgery data were excluded, loosing this information. Last year, while we were planning a new study about the use of biomarkers before surgery to predict risk in this kind of patients, we recovered this data to perform an exploratory analysis. Surprisingly, the results were interesting and reviewing the articles in last years, we felt that this data needed to be shared with others. No publication has explored the role of proANP or proADM in these patients until now, and we decided to work on this manuscript, focused exclusively on biomarkers before surgery to predict risk after surgery.

The blood sample was obtained in the Anaesthesia evaluation before cardiac surgery.

-Complicated outcome and major complications after pediatric cardiac surgery definitions should be consistent with literature. We advise to see and cite similar articles on other biomarkers.

-\>Dear Reviewer, thank you for your suggestion. We have added the definition of major complications according to the reference Cantinotti M, et al. Clin Chem Lab Med. 2015 Oct;53(11):1839-46 . The definition of poor outcome is based on previous studies (Gaies MG, et al. Pediatr Crit Care Med. 2014;15: 529--537), and we have decided to keep it in the article because our data revealed statistically significant differences regarding biomarkers and poor outcomes. In contrast, no differences were detected regarding biomarkers and major complications. However, a new analysis was made, considering major complications, and the new results have been included in table 3.

We also added the evaluation of respiratory support as intubation time after surgery, adding the reference suggested: Cantinotti M, et al. Clin Chem Lab Med. 2012 Nov;50(11):2009-17

Methods and results:

-Did you evaluate differences among neonates, infants, and children? If not, it may be of worth since for BNP the trend was quite different. You state something in the limitation section, but this point should be elucidated and detailed better, also in the tables.

-\>Dear reviewer, thank you for your suggestion. According to it, we evaluated the age-related differences. The division in 3 age groups was made based on the previous literature (Cantinotti M. Circ J. 2013;77(1):188-97. Line 123-124. The two biomarkers were analysed regarding the age-group, and differences were observed (new figure 2), such as the correlation biomarkers-age suggested. However the multivariate did not show differences, and 2 of the 3 newborns also presented major complications and high support in the PICU. We added information regarding age and biomarkers to the discussion section. A study that analysed proANP and proBNP showed that proANP presented a higher increased in the two first days of life and later presented a drop until normalize its levels since day 4th of life. In contrast, proBNP presented a lower increase but maintained high levels for more days after life (Mir TS, et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: Marked and rapid increase after birth. Pediatrics. 2003;112:896--899). Due to the differences between patients, we consider that more studies are needed to analyse separately newborns for being a special population, as we stated in the limitation subsection.

-In the tables please specify the type of CHDs

-\>Dear Reviewer, considering your suggestion, we have classified the patients in 3 categories according to a patho-physiological classification based on previous articles related to biomarkers (Especially Cantinotti et al.(2011) Review. Clin Chem Lab Med 49:567--580). Please, let us know if you consider that other classification is more suitable, such as the one based on the preoperative echocardiogram (Clancy, et al. J ThoracCardiovascSurg, 2000).

Class I: Two ventricle heart without arch obstruction 88 (77.9%)

Class II: Two ventricle heart with arch obstruction 8 (7.1%)

Class III: Single ventricle heart without arch obstruction 8 (7.1%)

Class IV: Single ventricle heart with arch obstruction 9 (8%)

-Inclusion/exclusion criteria are not well defined. Did you include only cardiopulmonary bypass surgery?

-\>Dear Reviewer, we included all the cardiac surgeries. Cardiopulmonary bypass was not required in two patients (2 Glenn procedures). We added this information to the table 1, and we also modified the explanation of the inclusion criteria.

Discussion: comparison with other biomarkers are required

-\>Dear Reviewer, we have added the comparison with the main prognostic biomarkers in cardiac surgery in children, the BNP and proBNP. Due to the length of the manuscript, the comparison is brief. Please, let us know if you consider that more information is required.

Limitation section need to implement.

-\>Dear Reviewer, the limitation subsection has been modified, especially the lack of comparison of proANP and proBNP. Our results confirm the usefulness of proANP in these patients, as you demonstrated regarding BNP and proBNP. This is the first time this analysis is performed. Afterwards, the comparison of these natriuretic peptides would be interesting. We chose proANP to explore new biomarkers and also to analyse the possibility to combine proANP and proADM to enhance our power of prediction, although our data did not confirm this.

Minor comments

CVC= I would rather use pediatric cardiac surgery without abbreviation

-\>Dear Reviewer, the abbreviation CVS was removed following your suggestion.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer \#2:

To the Authors

General Considerations

The aim of this study was to evaluate the utility of proANP and proADM determined before cardiovascular surgery for predicting need for high respiratory or inotropic support in the post-operative period. Authors enrolled 113 patients (51% males, median age 2.1 years, interquartile range 0.6-6.6 years) admitted to the neonatal intensive care unit after cardiovascular surgery. Authors considered as primary endpoints were a high respiratory support, considered as the need for more than 72 hours of mechanical ventilation after cardiovascular surgery, and a high inotropic support, in the first 24 hours after surgery. Furthermore, Secondary endpoints were the presence of complications after surgery, including Prolonged length of stay in ICU and mortality. The most important result of this study is that a high proANP determined before cardiovascular surgery may identify those patients who will need higher respiratory and inotropic support in the post-operative period.

The manuscript is concise and the results are clearly reported.

I have only one observation to address to the Authors. It is well known that B-type natriuretic peptides (especially BNP and NT-proBNP) are the first line biomarkers for screening of heart failure and are also reliable prognostic markers in children undergoing cardiac surgery (Authors should cite the important review: Cantinotti M et al. Heart Fail Rev 2014;19:727-42). Therefore, the original data related to this article are that also some A-type natriuretic peptides, such as proANP, can have a prognostic role in paediatric patients admitted to the neonatal intensive care. Authors should explain because clinicians should prefer the assay of proANP in respect to that of BNP or NT-proBNP in children undergoing cardiac surgery. Accordingly, an important limitation of this study is that Authors should due to compare the prognostic accuracy of proANP to that of BNP or NT-proBNP. Authors should discuss this important point in revised manuscript.

-\>Dear Reviewer, thank you very much for your comments. There are many studies focused on the usefulness of BNP and NT-proBNP in children undergoing cardiac surgery. We planned to explore new biomarkers different to BNP and NT-proBNP. The present study analysed two biomarkers that nobody had evaluated before paediatric cardiac surgery until now. As we said in the Discussion section: "One of the advantages of using these biomarkers is that after drawing the blood sample, the result is available in only 30 minutes. Moreover, previous studies in adults have reported non-inferiority of proANP with respect to brain natriuretic peptide in many cardiovascular diseases \[14,24\]. Because of these reasons, in our centre we decided to analyse them during the pre-surgery visit." Data regarding the comparison of proANP and proBNP have been added to the Discussion subsection.

As we stated in the limitations subsection, it is needed a comparison of proANP and NT-proBNP in these patients. However, we considered that these results are relevant as it is the first time that these biomarkers have been evaluated. Please, let us know if more information is required.

###### 

Submitted filename: Response to Reviewers.docx

###### 

Click here for additional data file.
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Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Authors correctly addressed all points raised by the reviewers.

I have just a request. If data have been partly already published, this should be clearly stated. Again, quite strange a prospective study date bake 2013

Reviewer \#2: Authors revised the manuscript in accordance with the suggestions made by the Reviewers. The manuscript is now significantly improved.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: **Yes: **Massimiliano Cantinotti

Reviewer \#2: No
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